Robust antibody response after the third mRNA coronavirus vaccination in Japanese hemodialysis patients

Robust antibody response after the third mRNA coronavirus vaccination in Japanese hemodialysis patients - Robust antibody response to the third mRNA vaccine in dialysis patients

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000049684

Enrollment

300

Registered

2022-12-04

Start date

2021-05-17

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19 in hemodialysis patients

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Persons who have cooperated in writing in this study

Exclusion criteria

Exclusion criteria: Patients with a history of COVID-19 prior to study entry or with a positive blood test for anti-SARS-CoV-2 IgG antibodies at the time of study entry

Design outcomes

Primary

Measure	Time frame
Positive rate of SARS-CoV-2 IgG antibody 2-3 weeks after 3 doses of BNT162b2 mRNA vaccine	—

Secondary

Measure	Time frame
Analysis of factors involved in the elevation of SARS-CoV-2 IgG antibodies in mRNA vaccines	—

Countries

Japan

Contacts

Public ContactRyoichi Miyazaki

Fujita Memorial Hospital Internal Medicine

ryoichi@mitene.or.jp0776-21-1277

Outcome results